The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
|Articles|October 22, 2012
VIDEO: Robert Frantz, MD, Talks About Bloodstream Infection Rates
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, discusses the rate of bloodstream infections in patients with pulmonary arterial hypertension treated with Veletri. Dr Franz also talks about the PROSPECT registry analysis.
Advertisement
Robert Frantz,
MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic,
discusses the rate of bloodstream infections in patients with pulmonary arterial hypertension treated with Veletri. Dr Franz also talks about the PROSPECT registry analysis.
This video was taken on Sunday, October 21 at the CHEST 2012 conference in Atlanta, GA.
Advertisement
Related to this article
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Advertisement
Advertisement